IPO Plus

₹273.8

▲ +7.41 +2.78%

05 Aug 2026

NSE Listed · Pharmaceuticals

Viyash Scientific Limited (VIYASH)

Volume: 26,50,237Avg Vol 1W: 19,32,279Avg Vol 1M: 14,30,38752W Range:₹166₹298
NSE BSE www.sequent.in AI Report
Key Ratios
Checked just now
Market Cap₹11,962 Cr
Current Price₹273.8
Previous Close₹266.39
High / Low (52w)₹298 / ₹166
Volume26,50,237
Avg Vol (1W)19,32,279
Avg Vol (1M)14,30,387
Stock P/E59.01
Book Value₹64.51
Dividend Yield0%
ROE7.07%
ROA443.72%
Revenue (TTM)—
Revenue Growth13.26%
Profit Margin5.2%
Total Debt₹274 Cr
Shares Outstanding44 Cr
Face Value₹2
EPS (TTM)₹4.64
P/B4.24
Debt / Equity0.21
50 DMA₹263.77
200 DMA₹223.96
Day change+2.78%
Price Chart
₹273.8▲ 53.04% · 1Y
₹294₹1682.3Cr
2025-08-05
2026-08-05

20-day avg volume: 13.8L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 830% YoY.
  • Net profit is growing year over year.
Cons
  • Stock trades at a high P/E of 59.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹390 Cr₹369 Cr₹774 Cr₹402 Cr₹441 Cr₹850 Cr₹858 Cr₹920 Cr
EBITDA₹28 Cr₹27 Cr₹48 Cr₹32 Cr₹41 Cr₹122 Cr₹131 Cr₹140 Cr
Net Profit₹7 Cr₹3 Cr₹45 Cr₹9 Cr₹14 Cr₹55 Cr₹38 Cr₹52 Cr
EPS————————
Profit & Loss (Annual)
MetricDec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026
Revenue₹338 Cr₹3,040 Cr₹42 Cr₹41 Cr₹340 Cr₹342 Cr₹3,464 Cr₹372 Cr
EBITDA₹42 Cr₹181 Cr₹7 Cr₹7 Cr₹38 Cr₹55 Cr₹462 Cr₹51 Cr
Net Profit₹51 Cr₹23 Cr₹4 Cr₹3 Cr₹23 Cr₹0 Cr₹177 Cr₹36 Cr
EPS—0.53————4.01—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹1,388 Cr₹1,463 Cr₹1,393 Cr₹1,451 Cr₹1,529 Cr₹1,540 Cr₹4,132 Cr₹4,628 Cr
Total Liabilities₹641 Cr₹731 Cr₹616 Cr₹711 Cr₹780 Cr₹827 Cr₹1,567 Cr₹1,514 Cr
Equity₹747 Cr₹732 Cr₹776 Cr₹740 Cr₹749 Cr₹713 Cr₹2,565 Cr₹3,115 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹115 Cr₹127 Cr₹159 Cr₹57 Cr₹31 Cr₹45 Cr₹394 Cr₹384 Cr
Investing₹-68 Cr₹-72 Cr₹10 Cr₹-96 Cr₹-65 Cr₹-6 Cr₹-447 Cr₹-84 Cr
Financing₹-20 Cr₹-43 Cr₹-139 Cr₹67 Cr₹32 Cr₹-1 Cr₹87 Cr₹-123 Cr
Free Cash Flow₹115 Cr₹127 Cr₹159 Cr₹57 Cr₹31 Cr₹45 Cr₹394 Cr₹384 Cr
Shareholding
Promoter 61.31% Institutions 8.26% Public 30.44%
Efficiency & Working Capital
ROCE13%
Interest Coverage6.6
Dividend Payout—
Debtor Days112 d
Inventory Days86 d
Payable Days64 d
Cash Conversion Cycle134 d
Working Capital Days197 d
Shareholding Details

As of 2026-06-30

Promoter61.3%
FII4.5%
DII3.8%
Institutions8.3%
Public30.4%
Promoter Pledge0%
No. of Shareholders1,28,367
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters52.8%52.8%52.8%52.8%52.8%52.6%52.6%52.6%52.3%61.4%61.3%61.3%
FIIs6%6.1%6.2%5.7%6.4%6.1%6%6.1%5.9%3.2%2.9%4.5%
DIIs3.2%5%7.6%8.1%10%12%12.8%13%12.9%7.4%8%3.8%
Public38%36.1%33.5%33.5%30.8%29.3%28.5%28.3%28.9%28.1%27.8%30.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,84,5211,72,8531,66,5931,63,6931,54,6031,62,5741,58,1521,47,3201,44,0851,34,1941,27,4461,28,367
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Ca Hull InvestmentsShareholding of Promoter and Promoter Group31.2%13.62 Cr
Ca Harbor InvestmentsShareholding of Promoter and Promoter Group30.1%13.17 Cr
Haribabu BodepudiPublic Shareholding2.8%1.21 Cr
Quant Mutual Fund - Quant Small Cap FundPublic Shareholding2.6%1.12 Cr
Kalidindi Srihari RajuPublic Shareholding2.4%1.03 Cr
Narasimha Reddy DuthalaPublic Shareholding1.3%55,44,570
Board of Directors
NameDesignationYear
Kamal K SharmaChairman & Independent Directo2026
Milind SarwateIndependent Non Exe. Director2026
Revati KastureIndependent Non Exe. Director2026
Anuj PoddarNon-Exec & Non-Independent Dir2026
Hari Babu BodepudiGroup CEO & Executive Director2026
N RajaramExecutive Director / Whole Time Director / CEO2026
Srinivas VasireddyExecutive Director / WTD / SVP / Head2026
Amit JainNon-Exec & Non-Independent Dir2026
Abhiroop JayanthiNon-Exec & Non-Independent Dir2026
YOSHITA SUSMIT VORACompany Sec. & Compli. Officer2026
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
Europe₹6 Cr3.8%
Asia₹141 Cr84.1%
Rest of the world₹20 Cr12.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹28868787
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-11Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20262,028001421242,293
20261,851001011022,054
2026120041355
Insider / Designated-Person Trades

30 recent disclosure(s)

Sequent Scientific Employee Stock Plan TrustDisposal · 5,50,000
Manish GuptaDisposal · 52,634
Manish GuptaDisposal · 1,03,498
Manish GuptaDisposal · 2,91,476
Manish GuptaDisposal · 98,032
Manish GuptaDisposal · 3,00,000
Substantial Acquisitions (SAST)

2 disclosure(s)

Scheme Of Amalgamation16/12/2025 · 13,61,60,231
Scheme Of Amalgamation16/12/2025 · 13,61,60,231
Company Information
Incorporated1985
ChairmanKamal K Sharma
AuditorSRBC & Co LLP
Investor Email[email protected]
🌐 www.sequent.in ↗

📍 301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl, Thane, Maharashtra, 400604

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Vital Chemtech LimitedViviana Power Tech Ltd.Vivid Electromech LimitedVisagar Polytex Ltd.Vivimed LabsVivo Collaboration Solutions Ltd.VL E-Governance & IT Solutions Ltd.V.L.Infraprojects LimitedVLS Finance Ltd.V Marc India LimitedVmart Retail Ltd.Vishal Mega Mart LimitedAll “V” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App